Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Product comparison
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

1 evidence topic · 1 source

PEAK comparison with sunitinib monotherapy

“mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy.” (opens the source at this quote in a new tab)